Implementation of a standardized voiding management protocol to reduce unnecessary re-catheterization - A quality improvement project.

Abstract:

OBJECTIVE:To design and implement a standardized postoperative voiding management protocol that accurately identifies patients with urinary retention and reduces unnecessary re-catheterization. METHODS:A postoperative voiding management protocol was designed and implemented in patients undergoing major, inpatient, non-radical abdominal surgery with a gynecologic oncologist. No patients had epidural catheters. The implemented quality improvement (QI) protocol included: 1) Foley removal at six hours postoperatively; 2) universal bladder scan after the first void; and 3) limiting re-catheterization to patients with bladder scan volumes >150 ml. A total of 96 patients post-protocol implementation were compared to 52 patients pre-protocol. Along with baseline demographic data and timing of catheter removal, we recorded the presence or absence of urinary retention and/or unnecessary re-catheterization and postoperative urinary tract infection rates. Fisher's exact test and student's t-tests were performed for comparisons. RESULTS:The overall rate of postoperative urinary retention was 21.6% (32/148). The new voiding management protocol reduced the rate of unnecessary re-catheterization by 90% (13.5% vs 2.1%, p = 0.01), without overlooking true urinary retention (23.1% vs 20.8%, p = 0.83). Additionally, there was a significant increase in hospital-defined early discharge prior to 11:00 AM (4.0% vs 22.0%, p = 0.022). There was no difference in the postoperative urinary tract infection rate between the groups (p = 1.00). Risk factors associated with urinary retention included older age (p < 0.01), use of medications with anticholinergic properties (p < 0.01), and preexisting urinary dysfunction (p < 0.01). CONCLUSIONS:Implementation of this new voiding management protocol reduced unnecessary re-catheterization, captured and treated true urinary retention, and facilitated early hospital discharge.

journal_name

Gynecol Oncol

journal_title

Gynecologic oncology

authors

Brackmann M,Carballo E,Uppal S,Torski J,Reynolds RK,McLean K

doi

10.1016/j.ygyno.2020.01.036

subject

Has Abstract

pub_date

2020-05-01 00:00:00

pages

487-493

issue

2

eissn

0090-8258

issn

1095-6859

pii

S0090-8258(20)30089-5

journal_volume

157

pub_type

杂志文章
  • Limited value of sonohysterography for endometrial screening in asymptomatic, postmenopausal patients treated with tamoxifen.

    abstract:OBJECTIVES:Sonohysterography (SHG) has been proposed as a useful tool for the surveillance of the endometrium in patients receiving tamoxifen. This study aimed to assess the value of SHG in asymptomatic patients who would have been biopsy candidates because of abnormal transvaginal ultrasound (TVUS) results. METHODS:T...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章

    doi:10.1006/gyno.2000.5876

    authors: Bertelli G,Valenzano M,Costantini S,Rissone R,Angiolini C,Signorini A,Gustavino C

    更新日期:2000-09-01 00:00:00

  • Gene expression profiling of in vitro radiation resistance in cervical carcinoma: a feasibility study.

    abstract:OBJECTIVE(S):To determine the feasibility of integrating an in vitro chemo-radiation response assay (IVRRA) with a gene microarray system to investigate the molecular patterns of expression that contribute to radiation resistance in cervical cancer. METHODS:Viable primary untreated cervical cancer specimens were obtai...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2005.05.043

    authors: Tewari D,Monk BJ,Al-Ghazi MS,Parker R,Heck JD,Burger RA,Fruehauf JP

    更新日期:2005-10-01 00:00:00

  • Management of uterine adenosarcomas with and without sarcomatous overgrowth.

    abstract:OBJECTIVES:Uterine adenosarcomas (AS) are rare tumors composed of malignant stromal and benign epithelial components. We sought to evaluate the role of primary surgery, adjuvant treatments, and salvage therapies for patients with uterine adenosarcomas. METHODS:We identified all patients diagnosed with AS from 1990 to ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2012.12.036

    authors: Tanner EJ,Toussaint T,Leitao MM Jr,Hensley ML,Soslow RA,Gardner GJ,Jewell EL

    更新日期:2013-04-01 00:00:00

  • Trends among gynecologic oncology inpatient deaths: is end-of-life care improving?

    abstract:OBJECTIVE:The objective was to describe trends over time in key factors surrounding end-of-life care on a gynecologic oncology service at a tertiary cancer center. METHODS:Patients with gynecologic cancers who were hospitalized and died at our institution between 1992 and 1997 were identified using institutional datab...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.2002.6616

    authors: Dalrymple JL,Levenback C,Wolf JK,Bodurka DC,Garcia M,Gershenson DM

    更新日期:2002-05-01 00:00:00

  • Disparities in surgical management of endometrial cancers in a public healthcare system: A question of equity.

    abstract:OBJECTIVE:Timely surgery has been shown to impact outcome in endometrial cancer patients. Social determinants of health (SDH) are associated with adverse cancer outcomes. We sought to evaluate the association of SDH with surgical treatment indicators in endometrial cancer patients in a public healthcare system. METHOD...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2020.08.029

    authors: Helpman L,Pond GR,Elit L,Anderson LN,Seow H

    更新日期:2020-11-01 00:00:00

  • Mutations in TAP genes are common in cervical carcinomas.

    abstract:OBJECTIVE:To determine whether squamous cervical cancers exhibit mutations or deletions in MHC class I genes or transport-associated protein (TAP) genes. METHODS:Polymerase chain reaction based protocols were used to examine HLA class I and TAP genes in a panel of cervical tumours, using DNA from corresponding blood s...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2003.11.037

    authors: Fowler NL,Frazer IH

    更新日期:2004-03-01 00:00:00

  • Brain metastases in patients with EOC: Clinico-pathological and prognostic factors. A multicentric retrospective analysis from the MITO group (MITO 19).

    abstract:BACKGROUND:Brain metastases (BM) from epithelial ovarian cancer (EOC) are considered a rare and unfavourable event. There is no consensus regarding the best management of these patients. METHODS:A multicenter retrospective analysis of patients with BM from EOC treated between 1997 and 2014 in 18 institutions of the MI...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.ygyno.2016.09.025

    authors: Marchetti C,Ferrandina G,Cormio G,Gambino A,Cecere S,Lorusso D,De Giorgi U,Bogliolo S,Fagotti A,Mammoliti S,Narducci F,Bergamini A,Scollo P,Biglia N,Breda E,Tamberi S,Marinaccio M,Angioli R,Salerno L,Eusebi MC,Loi

    更新日期:2016-12-01 00:00:00

  • Growth and differentiation of human papillomavirus type 31b positive human cervical cell lines.

    abstract::Human papillomavirus (HPV) containing cell lines derived from human cervical intraepithelial neoplasia (CIN) can offer valuable insights into the role of HPV in cervical neoplasia and can help in the understanding of the cellular changes that fuel the progression toward malignancy. We describe the growth and different...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1993.1131

    authors: De Geest K,Turyk ME,Hosken MI,Hudson JB,Laimins LA,Wilbanks GD

    更新日期:1993-06-01 00:00:00

  • Metabolic risk factors and mechanisms of disease in epithelial ovarian cancer: A review.

    abstract:OBJECTIVE:Epithelial ovarian cancer continues to be the deadliest gynecologic malignancy. Patients with both diabetes mellitus and obesity have poorer outcomes, yet research correlating metabolic abnormalities, such as metabolic syndrome, to ovarian cancer risk and outcomes is lacking. This article reviews the literatu...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.ygyno.2016.10.005

    authors: Craig ER,Londoño AI,Norian LA,Arend RC

    更新日期:2016-12-01 00:00:00

  • A longitudinal study of antigen expression in epithelial ovarian cancer.

    abstract::The extent to which the antigenic phenotype of human epithelial ovarian cancer changes during the course of the disease is an issue that must be addressed in order to maximize the potential of antibody-directed imaging and therapy. We have obtained tumor specimens at two separate operations from ten patients with epit...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(89)90179-0

    authors: Rubin SC,Finstad CL,Hoskins WJ,Federici MG,Lloyd KO,Lewis JL Jr

    更新日期:1989-09-01 00:00:00

  • Treatment of malignant ascites with allogeneic and autologous lymphokine-activated killer cells.

    abstract::Two cases of peritonitis carcinomatosa with gynecological cancer, which did not respond to conventional treatment, were treated by intraperitoneal adoptive immunotherapy with allogeneic or autologous lymphokine-activated killer (LAK) cells plus interleukin-2. In case 1, reduction of acute ascites and disappearance of ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(89)90101-7

    authors: Kamada M,Sakamoto Y,Furumoto H,Mori K,Daitoh T,Irahara M,Aono T,Nii A,Yanagawa H,Sone S

    更新日期:1989-07-01 00:00:00

  • Overall survival after pelvic exenteration for gynecologic malignancy.

    abstract:BACKGROUND:Five-Year survival after pelvic exenteration for gynecologic malignancies has been reported as high as 60%. The objective of this study was to determine overall survival (OS) after pelvic exenteration and evaluate factors impacting outcome. METHODS:A retrospective review of all women who underwent pelvic ex...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2014.06.034

    authors: Westin SN,Rallapalli V,Fellman B,Urbauer DL,Pal N,Frumovitz MM,Ramondetta LM,Bodurka DC,Ramirez PT,Soliman PT

    更新日期:2014-09-01 00:00:00

  • C-reactive protein and 6-keto prostaglandin F 1-alpha in patients with gynecologic cancer.

    abstract::C-reactive protein (CRP) is an acute phase reactant that appears to have a variety of biologic effects, including stimulation of prostaglandin production by peripheral blood monocytes. Both CRP and 6-keto prostaglandin F 1-alpha (6-keto PGF1-alpha) have been noted to be elevated in the sera of patients with malignant ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(90)90175-k

    authors: Terada K,Hayashi G,Hokama Y

    更新日期:1990-02-01 00:00:00

  • Adjunctive hysterectomy following radiation therapy for bulky carcinoma of the uterine cervix: prognostic implications of tumor persistence.

    abstract::Twenty-five patients underwent adjunctive extrafascial hysterectomy 14-60 days following completion of external and intracavitary irradiation for bulky carcinoma of the uterine cervix. Review of the operative histopathology and correlation with subsequent patient outcomes suggests that morphologically persistent cance...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(87)90217-4

    authors: Russell AH,Burt AR,Ek M,Russell KJ,Cain JM,Greer BE,Tamimi HK,Figge DC

    更新日期:1987-10-01 00:00:00

  • Prognostic value of endocervical sampling following loop excision of high grade intraepithelial neoplasia.

    abstract:OBJECTIVE:To assess the role of additional biopsies performed with loop electrosurgical excisional procedure (LEEP) in predicting the likelihood of persistent high grade intraepithelial neoplasia. METHODS:Clinicopathologic data were abstracted from women who underwent excision of high grade intraepithelial lesions bet...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2017.01.007

    authors: Cui Y,Sangi-Haghpeykar H,Patsner B,Bump JMM,Williams-Brown MY,Binder GL,Masand RP,Anderson ML

    更新日期:2017-03-01 00:00:00

  • Phenotypic and functional characteristics of mononuclear cells in ovarian carcinoma tumors.

    abstract::By using monoclonal antibodies and flow cytometry, the phenotype and activation state [based on presence of interleukin 2 (IL-2) receptors] were determined on the mononuclear cell (MNC) fraction of ovarian carcinoma tissue from 12 patients. Thymidine incorporation response to IL-2 and phytohemagglutinin stimulation wa...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(89)90128-5

    authors: Lentz SS,McKean DJ,Kovach JS,Podratz KC

    更新日期:1989-08-01 00:00:00

  • HLA-DQB1 and cervical cancer in Venezuelan women.

    abstract:BACKGROUND:Cervical cancer represents a major health problem in Venezuela as well as in other Latin American countries. High-risk human papillomavirus (HR-HPV) infection is known as the major risk factor of cervical cancer. However, whether or not a HR-HPV-infected woman progresses to cervical cancer may depend on the ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2004.10.002

    authors: Dao DD,Sierra-Torres CH,Robazetti SC,de Gomez MN,König R,Lema C,Lester LJ,Au WW,Tyring SK

    更新日期:2005-02-01 00:00:00

  • Comprehensive genomic profiling reveals inactivating SMARCA4 mutations and low tumor mutational burden in small cell carcinoma of the ovary, hypercalcemic-type.

    abstract:OBJECTIVE:Small cell carcinoma of the ovary, hypercalcemic-type (SCCOHT) is a rare, extremely aggressive neoplasm that usually occurs in young women and is characterized by deleterious germline or somatic SMARCA4 mutations. We performed comprehensive genomic profiling (CGP) to potentially identify additional clinically...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2017.09.031

    authors: Lin DI,Chudnovsky Y,Duggan B,Zajchowski D,Greenbowe J,Ross JS,Gay LM,Ali SM,Elvin JA

    更新日期:2017-12-01 00:00:00

  • Hexamethylmelamine as first-line chemotherapy in the treatment of advanced or recurrent carcinoma of the endometrium: a phase II trial of the Gynecologic Oncology Group.

    abstract::Thirty-eight patients with advanced or recurrent carcinoma of the endometrium who had received no prior chemotherapy were placed on study by the Gynecologic Oncology Group. One was deemed histologically ineligible. Three patients had insufficient trials to evaluate response. Of the remaining 34 who received hexamethyl...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/s0090-8258(88)80028-3

    authors: Thigpen JT,Blessing JA,Ball H,Hanjani P,Manetta A,Homesley H

    更新日期:1988-11-01 00:00:00

  • Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III.

    abstract:OBJECTIVES:SGN-00101 (HspE7, Nventa, San Diego, CA) is a novel therapeutic vaccine consisting of a fusion protein containing an M. bovis BCG heat shock protein (Hsp65) covalently linked to the entire sequence of HPV 16 E7. This trial was designed to evaluate the efficacy and toxicities of HspE7 in women with CIN III. ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.ygyno.2007.04.038

    authors: Einstein MH,Kadish AS,Burk RD,Kim MY,Wadler S,Streicher H,Goldberg GL,Runowicz CD

    更新日期:2007-09-01 00:00:00

  • 5-Fluorouracil (5-FU) and leucovorin in platinum-refractory advanced stage ovarian carcinoma.

    abstract::Twenty-nine patients with recurrent advanced stage ovarian cancer were treated with 5-fluorouracil (5-FU) and leucovorin by intravenous bolus on 5 consecutive days, repeated every 3 weeks. Twenty-one of these patients had experienced disease progression while receiving a cisplatin- or carboplatin-based regimen. There ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(92)90226-9

    authors: Reed E,Jacob J,Ozols RF,Young RC,Allegra C

    更新日期:1992-09-01 00:00:00

  • Analysis of the cost effectiveness of concurrent cisplatin-based chemoradiation in cervical cancer: implications from five randomized trials.

    abstract:PURPOSE:Five recent phase III trials provide strong evidence that a new alternative therapy, cisplatin-based chemoradiation, is more effective than standard therapy using radiation alone in the treatment of advanced cervical cancer. We conducted a pharmacoeconomic analysis to determine whether the alternative cisplatin...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1006/gyno.2000.5810

    authors: Rose PG,Lappas PT

    更新日期:2000-07-01 00:00:00

  • Recurrent squamous cell carcinoma of the cervix presenting as cardiac tamponade: case report and subject review.

    abstract::We describe a case in which the first recurrence of a cervical carcinoma presented as cardiac tamponade with circulatory collapse. We discuss the hemodynamics, clinical appearance, and management of metastatic-associated cardiac tamponade. ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(89)90148-0

    authors: Rudoff J,Percy R,Benrubi G,Ostrowski ML

    更新日期:1989-08-01 00:00:00

  • Prevention of venous thromboembolism in gynecologic oncology surgery.

    abstract::Gynecologic oncology patients are at a high-risk of postoperative venous thromboembolism and these events are a source of major morbidity and mortality. Given the availability of prophylaxis regimens, a structured comprehensive plan for prophylaxis is necessary to care for this population. There are many prophylaxis s...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.ygyno.2016.11.036

    authors: Barber EL,Clarke-Pearson DL

    更新日期:2017-02-01 00:00:00

  • A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.

    abstract:PURPOSE:Intraperitoneal (IP) therapy improves survival compared to intravenous (IV) treatment for women with newly diagnosed, optimally cytoreduced, ovarian cancer. However, the role of IP therapy in recurrent disease is unknown. Preclinical data demonstrated IP administration of the proteasome inhibitor, bortezomib pr...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.ygyno.2017.03.013

    authors: Jandial DA,Brady WE,Howell SB,Lankes HA,Schilder RJ,Beumer JH,Christner SM,Strychor S,Powell MA,Hagemann AR,Moore KN,Walker JL,DiSilvestro PA,Duska LR,Fracasso PM,Dizon DS

    更新日期:2017-05-01 00:00:00

  • Phase 2 trial of carboplatin plus tamoxifen in platinum-resistant ovarian cancer and primary carcinoma of the peritoneum.

    abstract:OBJECTIVES:A previously reported phase 2 trial suggested substantial clinical activity associated with the combination of a platinum agent and tamoxifen in the treatment of platinum-resistant ovarian cancer. We wished to confirm or refute this observation in a patient population with well-characterized platinum-resista...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章

    doi:10.1016/j.ygyno.2004.05.004

    authors: Markman M,Webster K,Zanotti K,Peterson G,Kulp B,Belinson J

    更新日期:2004-08-01 00:00:00

  • A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed müllerian tumors with evaluation of potential molecular targets.

    abstract:OBJECTIVE:The aim of this study was to determine the efficacy of cisplatin, ifosfamide, and mesna in uterine malignant mixed müllerian tumor (MMMT) and to evaluate the expression of clinically relevant molecular markers. METHODS:Women with advanced or recurrent MMMT were treated every 28 days with cisplatin (75 mg/m(2...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章

    doi:10.1016/s0090-8258(03)00332-9

    authors: Ramondetta LM,Burke TW,Jhingran A,Schmandt R,Bevers MW,Wolf JK,Levenback CF,Broaddus R

    更新日期:2003-09-01 00:00:00

  • MicroRNA miR-886-5p inhibits apoptosis by down-regulating Bax expression in human cervical carcinoma cells.

    abstract:OBJECTIVE:MicroRNA (miRNA) plays an essential role in the progression of a variety of cancers, but its role in cervical cancer progression is not well defined. We aimed to test whether special miRNAs and their target mRNAs contribute to cervical cancer progression. METHODS:The expression profiles of 1145 microRNAs in ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2010.09.009

    authors: Li JH,Xiao X,Zhang YN,Wang YM,Feng LM,Wu YM,Zhang YX

    更新日期:2011-01-01 00:00:00

  • Role of toll-like receptors in cervical, endometrial and ovarian cancers: a review.

    abstract:OBJECTIVE:The Toll-like receptors (TLRs) have been implicated in inflammation, innate immunity and cancer. The goal of this paper is to review the available published research about Toll-like receptors and their roles in gynecologic malignancies. METHODS:A Medline search was conducted and published articles from the l...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.ygyno.2014.08.013

    authors: Husseinzadeh N,Davenport SM

    更新日期:2014-11-01 00:00:00

  • Radical hysterectomy for cervical cancer: morbidity and survival in relation to weight and age.

    abstract::The records of 123 patients with Stage I cervical cancer who underwent radical hysterectomy with pelvic lymphadenectomy and para-aortic node sampling from 1981 to 1988 were reviewed to assess the risks of surgery associated with increasing weight and age. Fifty-four patients were obese (20% or more over ideal body wei...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(92)90312-7

    authors: Levrant SG,Fruchter RG,Maiman M

    更新日期:1992-06-01 00:00:00